AI in Drug Development: Progress and Challenges

“We didn’t start Model to launch a company — we started it because no one else met our standards,” says Dr. Daniel Haders II, CEO and founder of Model Medicines. On this episode of Vanguards of Health Care, Haders speaks with Bloomberg Intelligence analyst Andrew Galler about building an AI-native drug discovery engine capable of identifying cryptic binding pockets and designing first-in-class drugs. They unpack why hit rates and novelty must go hand-in-hand, an overview of the company’s pan-antiviral MDL-001, and why generalizability — not reinforcement learning — is the true litmus test for AI in biotech.

See omnystudio.com/listener for privacy information.